Cytokinetics to Participate in May Investor Conferences

Company Overview - Cytokinetics is a specialty cardiovascular biopharmaceutical company with over 25 years of experience in muscle biology, focusing on developing new medicines for cardiac muscle dysfunction [2] - The company is preparing for potential regulatory approvals and commercialization of aficamten, a cardiac myosin inhibitor, following positive results from the SEQUOIA-HCM Phase 3 clinical trial for obstructive hypertrophic cardiomyopathy (HCM) [2] - Cytokinetics is also developing omecamtiv mecarbil for heart failure with severely reduced ejection fraction (HFrEF), CK-586 for heart failure with preserved ejection fraction (HFpEF), and CK-089 for specific muscular dystrophies and impaired skeletal muscle function [2] Upcoming Events - The management team will participate in a fireside chat at The Citizens Life Sciences Conference on May 7, 2025, at 10:00 AM Eastern Time in New York [5] - The management team will also participate in the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025, at 8:30 AM Eastern Time in New York [5] Investor Access - Interested parties can access live webcasts of the fireside chats through the Investors & Media section of the Cytokinetics website, with replays archived for 90 days post-event [1]